Physician profile
Mark Dylewski
NPI 1235136151
$278,662.01
in general payments reported to CMS, 2019-2025
23 companies · $21K in 2025
The $21K reported for 2025 was more than what 94% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $46K · 2021: $27K · 2022: $14K · 2023: $64K · 2024: $60K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $71K · Consulting Fee: $45K · Food and Beverage: $13K · Travel and Lodging: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $71,160.28 |
| Consulting Fee | $44,639.78 |
| Food and Beverage | $13,289.35 |
| Travel and Lodging | $10,724.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $173,832.66 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Ethicon INC. | $70,881.61 | 2019-2025 | Monarch Platform, Echelon; Endopath |
| Medical Device Business Services, INC. | $11,381.50 | 2019-2025 | Echelon Flex, Echelon; Endopath, Echelon Endopath |
| Noah Medical Corporation | $7,692.22 | 2023 | |
| Atricure, INC. | $3,951.81 | 2022-2025 | Atricure Cryoice Cryoablation System (Cryo2), Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System |
| Ethicon Endo-Surgery INC. | $3,454.32 | 2019-2022 | |
| Davol INC. | $2,602.52 | 2019-2025 | Progel Applicator Spray Tips, Arista Ah Flexitip |
| Ethicon US, LLC | $2,360.14 | 2019-2025 | Echelon; Endopath, Echelon Endopath, Vistaseal |
| Medtronic, INC. | $811.00 | 2023 | |
| Zimmer Biomet Holdings, INC. | $603.17 | 2019-2024 | Advantagerib, Sternalock Blu System |
| On Target Laboratories, INC | $361.00 | 2025 | Cytalux |
| Covidien LP | $138.06 | 2020 | |
| Becton, Dickinson and Company | $97.45 | 2019 | |
| Veran Medical Technologies, INC. | $85.22 | 2019 | |
| Caris Mpi, INC. | $76.72 | 2025 | Mi Cancer Seek |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $75.00 | 2019 | |
| Karl Storz Endoscopy-America | $74.42 | 2019 | |
| Boston Scientific Corporation | $52.35 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $49.88 | 2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $32.50 | 2025 | Tagrisso |
| Tempus Ai, INC | $25.00 | 2024 | Xt Cdx |
| Janssen Biotech, INC. | $23.46 | 2024 | Rybrevant |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dylewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.